Amy Levál
Impact in
- Psychiatry and Mental health top 2%
- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- Biological Psychiatry top 5%
Papers in ⓘ
-
- Tryptophan and brain disorders 3
- Co-authors
- Jari Tiihonen (8 shared papers)Fabian Hoti (6 shared papers)Juha Mehtälä (8 shared papers)Heidi Taipale (6 shared papers)Dana Enkusson (6 shared papers)Erik Jedenius (6 shared papers)Ellenor Mittendorfer‐Rutz (6 shared papers)Antti Tanskanen (6 shared papers)
- Journals
- PLoS ONE (5 papers)JAMA Psychiatry (4 papers)European Neuropsychopharmacology (4 papers)Vaccine (2 papers)European Journal Of Haematology (2 papers)
- Partner nations
- SwedenFinlandUnited States
In The Last Decade
Amy Levál
38 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Psychiatry and Mental health 630
- Biological Psychiatry 84
- Philosophy 172
- Clinical Psychology 239
- Epidemiology 354
Countries citing papers authored by Amy Levál
This map shows the geographic impact of Amy Levál's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Levál with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Levál more than expected).
Fields of papers citing papers by Amy Levál
This network shows the impact of papers produced by Amy Levál. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Levál. The network helps show where Amy Levál may publish in the future.
Co-authors
The 25 scholars most cited alongside Amy Levál, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia Hit paper breakdown → | 2017 | 438 |
| 2 | 2017 | 178 | |
| 3 | 2013 | 113 | |
| 4 | 2012 | 79 | |
| 5 | 2014 | 73 | |
| 6 | 2022 | 65 | |
| 7 | 2020 | 50 | |
| 8 | 2020 | 47 | |
| 9 | 2011 | 45 | |
| 10 | 2010 | 30 | |
| 11 | 2015 | 29 | |
| 12 | 2004 | 28 | |
| 13 | 2018 | 28 | |
| 14 | 2010 | 25 | |
| 15 | 2018 | 25 | |
| 16 | 2023 | 22 | |
| 17 | 2015 | 17 | |
| 18 | 2017 | 16 | |
| 19 | 2018 | 15 | |
| 20 | 2016 | 13 |
About Amy Levál
Amy Levál is a scholar working on Biological Psychiatry, Microbiology, Modeling and Simulation, Psychiatry and Mental health and Speech and Hearing, having authored 40 papers that have together received 1.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (6 papers), Schizophrenia research and treatment (5 papers), Cervical Cancer and HPV Research (5 papers), Hepatitis B Virus Studies (4 papers), Prostate Cancer Diagnosis and Treatment (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Genital Health and Disease (4 papers) and Tryptophan and brain disorders (3 papers). The work is most often cited by research in Psychiatry and Mental health (630 citations), Biological Psychiatry (84 citations), Philosophy (172 citations), Clinical Psychology (239 citations) and Epidemiology (354 citations). Amy Levál has collaborated with scholars based in Sweden, Finland and United States. Frequent co-authors include Jari Tiihonen, Fabian Hoti, Juha Mehtälä, Heidi Taipale, Dana Enkusson, Erik Jedenius, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jan Sermon and Maila Majak. Their work appears in journals such as PLoS ONE, JAMA Psychiatry, European Neuropsychopharmacology, Vaccine and European Journal Of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.